FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 680 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Immunotherapy Effective in Alveolar Soft Part Sarcoma January 9, 2019 FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... April 9, 2024 An integral part of research September 21, 2022 A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... July 11, 2024 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab Registered Dietitian vs. Nutritionist Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small... Dad Is Making Baby Giggle, But When He Makes A Sheep...
